Zacks: Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.13 Per Share

Brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings per share of ($0.13) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). ZIOPHARM Oncology posted earnings per share of ($0.11) during the same quarter last year, which indicates a negative year-over-year growth rate of 18.2%. The company is scheduled to report its next earnings report on Thursday, February 15th.

On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.54) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.52). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.64) to ($0.53). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same period in the previous year, the company posted ($0.11) EPS. ZIOPHARM Oncology’s revenue for the quarter was up .0% compared to the same quarter last year.

Several equities analysts have recently commented on ZIOP shares. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. HC Wainwright reaffirmed a “buy” rating and issued a $9.50 target price on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday, November 10th. Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Finally, BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. ZIOPHARM Oncology has an average rating of “Hold” and an average price target of $12.75.

In related news, CEO Laurence James Neil Cooper purchased 6,440 shares of ZIOPHARM Oncology stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the transaction, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.40% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in ZIOPHARM Oncology by 7.6% during the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in ZIOPHARM Oncology during the third quarter worth $145,000. Tudor Investment Corp ET AL lifted its stake in ZIOPHARM Oncology by 390.4% during the second quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 50,395 shares during the last quarter. Northern Trust Corp lifted its stake in ZIOPHARM Oncology by 10.1% during the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after purchasing an additional 149,067 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in ZIOPHARM Oncology by 6.8% during the second quarter. TIAA CREF Investment Management LLC now owns 350,435 shares of the biotechnology company’s stock worth $2,180,000 after purchasing an additional 22,348 shares during the last quarter. 40.23% of the stock is currently owned by institutional investors and hedge funds.

ZIOPHARM Oncology (ZIOP) remained flat at $$4.38 during trading on Friday. 1,215,800 shares of the company traded hands, compared to its average volume of 1,708,500. ZIOPHARM Oncology has a 52-week low of $3.90 and a 52-week high of $7.88. The company has a market cap of $621.80, a price-to-earnings ratio of -8.42 and a beta of 1.44.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/05/zacks-brokerages-expect-ziopharm-oncology-inc-ziop-will-announce-earnings-of-0-13-per-share.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply